用于缓解功能性便秘的果酸寡糖:随机对照试验的系统审查和元分析
Hongmin Zhen1, Hanwei Qian1, Xiaoyan Liu2
1Key Laboratory of Geriatric Nutrition and Health, Ministry of Education, China-Canada Joint Lab of Food Nutrition and Health, Beijing Technology and Business University (BTBU), Beijing 100048, China.
Foods (Basel, Switzerland)
|January 8, 2025
概括
果脂糖 (FOS) 通过增加肠道排便频率和软化便,显著改善便秘. 虽然通常是安全的,但可能会出现轻微的膨胀,这需要进一步研究以获得最佳使用.
科学领域:
- 胃肠病学 胃肠病学
- 营养科学 营养科学
- 微生物学 微生物学
背景情况:
- 便秘是一种普遍的胃肠道疾病,影响生活质量.
- 益生菌,如果醇糖 (FOS),被认为具有调节肠道微生物群和改善肠道功能的潜力.
- 饮食补充FOS正在被探索作为一种非药物治疗方法来治疗便秘.
研究的目的:
- 系统地审查和对随机对照试验 (RCT) 的元分析,评估果酸寡糖 (FOS) 作为治疗便秘的食补充剂的疗效.
- 评估FOS对肠道排便频率,便一致性,胃肠道过渡时间和相关症状的影响.
- 为了确定与FOS消费相关的任何不良事件.
主要方法:
- 在主要数据库 (Cochrane Library,PubMed,EMBASE,Web of Science) 进行了全面的搜索,截至2024年3月2日.
- 包括的RCT使用Cochrane风险偏差工具评估了偏差风险.
- 数据使用随机效应或固定效应模型进行合成,结果报告为几率比率 (OR),加权平均差异 (MD) 或标准化平均差异 (SMD) 与95%置信区间 (CI).
主要成果:
- 分析包括17个RCT与713名参与者.
- 摄入FOS显著增加了肠道排便频率 (p < 0.00001) 和改善了便的一致性 (SMD: 0.36).
- 观察到排便过程中减轻了努力和疼痛 (SMD: -0.60),轻度胀气被报告为主要不良事件 (OR: 10.36).
结论:
- 果酸糖体显示出作为一种饮食补充剂的潜力,可以提高肠道排便的频率和改善便秘症状.
- 虽然FOS通常看起来是安全的,但应该考虑轻微的胃肠道不适,如胀气.
- 需要进一步的高质量的RCT来确定最佳剂量并确认功能性便秘治疗的有效性.
更多相关视频
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
131
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
131
Drugs for Treatment of Diarrhea-Predominant IBS
146
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
146
Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
186
Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This...
186
Drugs Affecting GI Tract Motility: Other Laxatives
164
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
164
Irritable Bowel Syndrome III: Medical and Nursing Management
166
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
166
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
206
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
206


